ZETA SURGICAL's Revolutionary Zeta TMS Navigation System Begins Commercial Use at HOPE Therapeutics

ZETA SURGICAL Launches First Commercial Deployment of Zeta TMS Navigation System

On May 26, 2026, ZETA SURGICAL made a significant announcement, marking a milestone in the treatment of Major Depressive Disorder (MDD) and other neurological conditions. The company revealed the first commercial use of its FDA-cleared Zeta TMS Navigation System at HOPE Therapeutics, located in West Palm Beach, Florida. This advanced technology aims to deliver high-precision Transcranial Magnetic Stimulation (TMS), a non-invasive therapy primarily utilized for treatment-resistant depression, which impacts nearly one-third of major depression patients worldwide.

The efficacy of TMS relies on the precise targeting of specific neural circuits. To address this critical need, the Zeta TMS Navigation System employs RealTrack™ technology, offering real-time, markerless image guidance. By integrating computer vision and artificial intelligence, the system aligns a patient’s MRI or CT scan with their facial features continuously, achieving sub-millimeter precision. Notably, it reduces setup times to under two minutes per session without the necessity for traditional fiducial markers, making it a game-changer in outpatient neuro-therapeutic workflows.

Dr. William Gormley, Co-Founder of ZETA SURGICAL and Director of Neurosurgical Innovation at Mass General Brigham, expressed the company’s commitment to accessibility in precision image guidance across various clinical environments. “With the Zeta TMS platform, we are bringing a level of targeting accuracy that is typically reserved for the neurosurgical operating room directly into outpatient psychiatric and neurological care,” he stated.

Vincent Lan, Chief Business Officer at ZETA SURGICAL, highlighted that this commercial launch signifies a transition from research and development to practical application. The West Palm Beach center of HOPE Therapeutics was described as an ideal site due to its reputation in mental health treatments, emphasizing the partnership's potential to enhance patient outcomes. The integration of ZETA’s technology into their neuro-therapeutic practices underlines their commitment to offering advanced, evidence-based treatments.

Dr. Rebecca Cohen, Medical Director of HOPE Therapeutics, acknowledged the benefits of ZETA's innovative approach. She stated, “ZETA's technology allows us to administer TMS with enhanced precision, and we are looking forward to the impact this will have on our clinical practice.” This sentiment reflects the broader aspiration of integrating cutting-edge technology into standard care to improve the effectiveness of treatments.

The deployment at HOPE Therapeutics follows ZETA SURGICAL achieving several regulatory milestones, including multiple FDA 510(k) clearances for its neuronavigation tools and approval of patents related to its artificial intelligence technology. These advancements not only underscore the company’s innovative drive but also its capability to revolutionize neuro-therapeutics.

For more insight into the Zeta TMS Navigation System, interested parties are encouraged to visit www.zetasurgical.com. ZETA SURGICAL promises to redefine the standards of care for image-guided surgery and targeted neuro-therapeutics through its pioneering navigation and robotics platform. The Zeta Navigation System, in particular, offers high-accuracy image guidance, facilitating less invasive, more precise treatment options across various clinical settings.

As HOPE Therapeutics embarks on this partnership with ZETA SURGICAL, the horizons for mental health treatment are broadening, promising improved intervention for those battling major depressive disorder and related neurological conditions.